Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion–related acute lung injury in a two-event animal model

Authors

  • Li Zhi,

    1. From the Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
    Search for more papers by this author
  • Xuan Chi,

    1. From the Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
    Search for more papers by this author
  • Monique P. Gelderman,

    1. From the Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
    Search for more papers by this author
  • Jaroslav G. Vostal

    Corresponding author
    1. From the Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
      Jaroslav G. Vostal, MD, PhD, Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, FDA, Building 29, Room 321, HFM 335, 8800 Rockville Pike, Bethesda, MD 20892; e-mail: jaroslav.vostal@fda.hhs.gov.
    Search for more papers by this author

  • The findings and conclusions in this manuscript have not been formally disseminated by the FDA and should not be construed to represent any Agency determination or policy.

Jaroslav G. Vostal, MD, PhD, Laboratory of Cellular Hematology, Division of Hematology, OBRR, Center for Biologics Evaluation and Research, FDA, Building 29, Room 321, HFM 335, 8800 Rockville Pike, Bethesda, MD 20892; e-mail: jaroslav.vostal@fda.hhs.gov.

Abstract

BACKGROUND: We recently reported that infusion of ultraviolet light B (UVB)-exposed human platelets (HPs) can be the second event that mediates acute lung injury (ALI) in a two-event mouse model of transfusion-related acute lung injury (mTRALI). We have now identified changes in HPs induced by UVB light and responses of the recipient animal that mediate the mTRALI.

STUDY DESIGN AND METHODS: Effects of UVB on HPs were monitored by flow cytometry and aggregation. HPs exposed to UVB, with or without inhibitors to specific biochemical pathways, were infused into lipopolysaccharide (LPS)-primed severe combined immunodeficient (SCID) mice. ALI was monitored by protein elevations in bronchoalveolar lavage fluid (BALF).

RESULTS: UVB increased fibrinogen binding and potentiated HP aggregation. Infusion of UVB HPs into LPS-primed SCID mice led to macrophage inflammatory protein 2 (MIP-2) elevations in plasma and BALF and resulted in ALI. Protein kinase C (PKC) inhibitors prevented UVB-induced HP changes in vitro and reduced MIP-2 elevation and mTRALI in vivo. Blocking of fibrinogen binding to HP αIIbβ3 with c7E3 monoclonal antibody prevented mTRALI. MIP-2 elevation in vivo in response to UVB HPs was essential for ALI since blocking of MIP-2 receptor in vivo prevented mTRALI.

CONCLUSION: PKC signaling mediates UVB-induced HP fibrinogen binding and aggregation in vitro. The host animal responds to an infusion of UVB HPs by MIP-2 elevation that mediates downstream mTRALI. Elucidation of molecular mechanisms in UVB HP–mediated mTRALI may provide insight into pulmonary adverse events reported with UV-irradiated pathogen-reduced platelets.

Ancillary